Rosiglitazone, thiazolidinediones and atherosclerosis.
Dandona
Paresh
P
Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo and Kaleida Health, 3 Gates Circle, Buffalo, NY 14209, USA. pdandona@KaleidaHealth.org
Chaudhuri
Ajay
A
Ghanim
Husam
H
D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D050197:Atherosclerosis / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000628:therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007249:Inflammation; D007333:Insulin Resistance; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D009569:Nitric Oxide / Q000378:metabolism; D009765:Obesity / Q000150:complications; D017382:Reactive Oxygen Species; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D007004:Hypoglycemic Agents; D017382:Reactive Oxygen Species; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D009569:Nitric Oxide